PONIARD PHARMA PARD (NASDAQ)

(NEW YORK)Data presented over the weekend on Bristol-Myers Squibb/ImClone Systems Inc.'s colorectal cancer treatment Erbitux could provide doctors a better way of treating the disease.READ MORE

(NEW YORK)With cancer drugs making up the bulk of sales for many biotech companies, Wall Street is gearing up for one of the year's most anticipated medical conferences, the American Soc...READ MORE

(NEW YORK)Analysts said Celgene Corp. and Genentech Inc. are their top picks heading into the 44th annual American Society of Clinical Oncology meeting, or ASCO, taking place May 30 to June ...READ MORE

(SOUTH SAN FRANCISCO, Calif.)Poniard Pharmaceuticals Inc. said Wednesday its lung cancer drug picoplatin continued to extend patient survival in mid-stage studies. The company said the latest results confirmed...READ MORE

(NEW YORK) Early-stage and preclinical cancer treatment research dominated the American Association of Cancer Research's annual meeting this weekend. Late Sunday, Thousand Oaks, Calif.-...READ MORE

(SOUTH SAN FRANCISCO, Calif.)Poniard Pharmaceuticals Inc., an oncology-focused biopharmaceutical company, on Wednesday said W. C. Heraeus GmbH will commercially make and supply its picoplatin drug, which is be...READ MORE

(NEW YORK)Data from ongoing colon cancer therapy studies will soon show if several drugs already on the market are more effective at treating patients who have the K-ras gene, which is typic...READ MORE